T
he Association of British Neurologists' (ABN) management guideline recommends beta interferon or glatiramer acetate (GLAT) as first-line therapy for adults with active relapsing-remitting multiple sclerosis (RRMS) that is not rapidly evolving. 1 Both treatments are administered by injection, which is a barrier to adherence for some patients. [2] [3] [4] NICE has now recommended oral teriflunomide as an option for first-line therapy. 2 The ABN guideline will soon be out of date, and current practice is for clinicians and patients to choose a drug, taking into account the course and severity of the patients' MS, lifestyle issues, route and schedule of administration, the side-effect profile and storage requirements. 5 Dimethyl fumarate (DMF; Tecfidera), another oral drug for patients with RRMS, is likely to be NICE approved soon, and will be an alternative first-line therapy for people with RRMS who do not qualify for treatment with natalizumab. DMF could also have a role after failure of an interferon or GLAT.
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Dimethyl fumarate
DMF has been licensed by the EMA and FDA for treatment of adults with RRMS. Its mechanism of action is uncertain but appears to be mediated through activation of the nuclear factor (erythroidderived 2)-like 2 (Nrf2) transcriptional pathway, promoting anti-inflammatory activity and inhibiting pro-inflammatory cytokines and adhesion molecules.
Treatment is initiated at a dosage of 120mg twice daily with food, increased to 240mg twice daily after one week. Renal and hepatic function should be assessed before treatment, after three and six months, and then every six to 12 months. DMF may decrease the lymphocyte count; a full blood count is recommended before treatment, after six months, and then every six to 12 months.
No dose adjustment is recommended for the elderly, nor in patients with impaired renal or hepatic function, however DMF should be prescribed with caution in older people. It is contraindicated in patients with severe renal or hepatic impairment or severe active gastrointestinal disease, and during pregnancy.
Clinical trials
Two phase 3 trials have compared DMF 240mg twice daily with placebo: DEFINE (n=1234) 6 and CONFIRM (n=1417). 7 Both trials included a three times daily treatment arm, but only data for the twice daily 
KEY POINTS
n dimethyl fumarate (Tecfidera) is licensed for the treatment of adults with relapsing-remitting multiple sclerosis n it has anti-inflammatory properties but its mechanism of action is uncertain n the recommended dosage is initially 120mg then 240mg twice daily orally with food n a month's treatment on the maintenance dose costs £1373
n compared with placebo, it significantly reduced relapse rates and new brain lesions after two years' treatment n a reduction in disability progression has not consistently been shown in the two pivotal phase 3 trials, although post hoc analyses suggest such an effect n common adverse effects include flushing and gastrointestinal events, low white cell count, pruritus, rash and proteinuria dose are discussed here. CONFIRM included GLAT 20mg per day as a 'reference' but was not designed to assess whether DMF was superior or non-inferior. Both trials included patients aged 18-55 with RRMS, and a score of ≤5 on the Expanded Disability Status Scale (EDSS), plus at least one clinically documented relapse in the previous 12 months or at least one gadolinium-enhancing lesion up to six weeks before randomisation. The primary endpoint of DEFINE was the proportion of patients who had a relapse by two years; for CONFIRM, it was the annualised relapse rate (ARR) at two years. About 20 per cent of patients in each study discontinued treatment.
In DEFINE, relapses occurred in significantly fewer patients treated with DMF (27 vs 46 per cent with placebo, p<0.001); the ARR after two years was 0.17 compared to 0.36 with placebo (p<0.001). DMF prolonged the time to first relapse (87 vs 38 weeks with placebo in the 25th percentile of patients) and reduced the risk of confirmed disability progression over two years (hazard ratio 0.62, 95 per cent CI, 0.44-0.87; p=0.005). On MRI, DMF reduced the mean numbers of new or enlarging T2-weighted lesions at two years (2.6 vs 17.0 with placebo) and gadolinium-enhancing T1-weighted lesions (0.1 vs 1.8).
In CONFIRM, the ARR was 0.22 with DMF and 0.40 with placebo (p<0.001); the ARR for GLAT was 0.29. The proportions of patients with relapse after two years were 29, 41 and 32 per cent, respectively. Neither DMF nor GLAT significantly reduced disability progression at six months. The mean number of new or enlarging T2-weighted lesions on MRI at two years was reduced by DMF (3.0 vs 7.0 with placebo; 4.1 with GLAT); it also reduced the number of gadoliniumenhancing lesions on T1-weighted MRI (0.5 vs 2.0; 0.7 with GLAT).
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Place in therapy
Klaus Schmierer DMF is a welcome addition to the new batch of disease-modifying treatments (DMTs) for people with RRMS. It is the third oral DMT available to patients on the NHS, and the second first-line DMT following the recent release of teriflunomide (fingolimod is licensed only for RRMS failing treatment with first-line injectable DMT).
DMF reduces the relapse rate across a broad spectrum of people with RRMS, 1 however its potential is probably greatest in recently diagnosed patients, 2 ie not in people with rapidly evolving or highly active RRMS, for whom other treatments (natalizumab, alemtuzumab) will be more appropriate.
While there is unequivocal evidence for a significant effect on relapses (about 50 per cent reduction relative to placebo), efficacy on disability endpoints has so far been less convincing and awaits confirmation following longer term observation. However, taking into account the significant effect of DMF on relapses and MRI predictors of disability, such as the number of T 1 hypo-intense lesions ('black holes'), and brain atrophy (30 per cent relative reduction compared to placebo between months 6 and 24), it is likely that DMF will also be effective in limiting disability progression. 3 The data collected so far suggest that DMF is more effective than GLAT and -albeit not compared directly -beta-interferons. It is therefore likely that the use of first injectable DMT (GLAT and beta-interferons) will diminish substantially.
Key adverse effects of DMF are flushing, abdominal pain, diarrhoea, nausea, pruritus, proteinuria and lymphopenia. Although these appear manageable in most cases, and gastrointestinal side-effects diminish over about one month, one should expect that about 20 per cent of patients will not tolerate DMF long term.
The twice-daily dosing frequency is a slight disadvantage compared to drugs that need to be taken only once daily. However, neither this minor inconvenience, nor the overall modest side-effect profile are likely to impact on the uptake by UK neurologists eager to prescribe DMF to their patients with RRMS.
As this article goes into press a case of progressive multifocal leukencephalopathy (PML) has been reported in a patient with MS who eventually died of pneumonia. Apparently, the patient had been taking DMF for more than five years and developed significant long term lymphopenia. Lymphopenia is a known risk factor for PML, and our empiric advice at this stage would be to prevent the lymphocyte count in patients treated with DMF from dropping lower than 0.8x10 9 per litre (WHO grade 1-2 toxicity). 4 
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